Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + docetaxel for asymptomatic brain metastases after frontline immunotherapy resistance in advanced NSCLC
ChiCTR2500095273Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: intracranial progression-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
cadonilimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500095273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095273.